NCT02956798View on ClinicalTrials.gov

SAbR For Oligometastatic Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions
Oligometastatic Renal Cell Carcinoma
Interventions
RADIATION

Stereotactic ablative body radiation (SABR)

SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER